Линвосельтамаб

C₆₄₅₅H₉₉₅₅N₁₇₂₁O₂₀₃₉S₄₇

• Молярная масса: 145800,47 г/моль
• Химическое название: immunoglobulin G4-kappa, anti-[Homo sapiens TNFRSF17 (TNF receptor superfamily member 17, tumor necrosis factor receptor superfamily, member 17, B cell maturation antigen, BCMA, BCM, TNFRSF13A, CD269)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], Homo sapiens monoclonal antibody;
  gamma4 heavy chain anti-TNFRSF17 Homo sapiens (1-451) [VH (Homo sapiens IGHV3-7*01 (93.9%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.18] (26-33.51-58.97-114)) (1-125) -Homo sapiens IGHG4*01, G4v5 h P10, G4v7 CH2 del 1.4, P1.3, V1.2, A1.1 (G2-like) (CH1 (126-223), hinge 1-12 S10>P (233) (224-235), CH2 ‘E1.4,F1.3’>P1.3 (238), L1.2>V (239), G1.1>A (240) (236-344), CH3 (345-449), CHS (450-451)) (126-451)], (139-215')-disulfide with kappa light chain Homo sapiens (1'-215') [V-KAPPA (Homo sapiens IGKV1-39*01 (100%) -IGKJ5*01 (100%), CDR-IMGT [6.3.10] (27-32.50-52.89-98)) (1'-108') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')];
  gamma4 heavy chain anti-CD3E Homo sapiens (1''-450'') [VH (Homo sapiens IGHV3-9*01 (98.0%) -(IGHD) -IGHJ1*01 (90.9%) L123>T (119), CDR-IMGT [8.8.17] (26-33.51-58.97-113)) (1''-124'') -Homo sapiens IGHG4*01, G4v5 h P10, G4v8 CH3 R115, F116, P125 (CH1 (125''-222''), hinge 1-12 S10>P (232) (223''-239''), CH2 (240''-343''), CH3 H115>R (438), Y116>F (439), L125>P (448) (G3-like) (344''-448''), CHS (449''-450'')) (125''-450'')], (138''-215''')-disulfide with kappa light chain Homo sapiens (1'''-215''') [V-KAPPA (Homo sapiens IGKV1-39*01 (100%) -IGKJ5*01 (100%), CDR-IMGT [6.3.10] (27-32.50-52.89-98)) (1'''-108''') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'''-215''')]; dimer (231-230'':234-233'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
• АТХ код: L01FX37
• Drugbank: DB17447
• CAS: 2408319-25-3
• Структура

Информация о действующем веществе Линвосельтамаб предназначена для медицинских и фармацевтических специалистов, исключительно в справочных целях.